- Home
- GLTO vs PW Comparison
GLTO vs PW Comparison
Compare GLTO & PW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- PW
- Stock Information
- Founded
- GLTO 2011
- PW 1967
- Country
- GLTO Denmark
- PW United States
- Employees
- GLTO N/A
- PW N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- PW Real Estate Investment Trusts
- Sector
- GLTO Health Care
- PW Real Estate
- Exchange
- GLTO Nasdaq
- PW Nasdaq
- Market Cap
- GLTO 4.5M
- PW 4.0M
- IPO Year
- GLTO 2020
- PW N/A
- Fundamental
- Price
- GLTO $3.21
- PW $1.19
- Analyst Decision
- GLTO Buy
- PW
- Analyst Count
- GLTO 1
- PW 0
- Target Price
- GLTO $10.00
- PW N/A
- AVG Volume (30 Days)
- GLTO 29.8K
- PW 26.7K
- Earning Date
- GLTO 08-11-2025
- PW 08-11-2025
- Dividend Yield
- GLTO N/A
- PW N/A
- EPS Growth
- GLTO N/A
- PW N/A
- EPS
- GLTO N/A
- PW N/A
- Revenue
- GLTO N/A
- PW $3,001,057.00
- Revenue This Year
- GLTO N/A
- PW N/A
- Revenue Next Year
- GLTO N/A
- PW N/A
- P/E Ratio
- GLTO N/A
- PW N/A
- Revenue Growth
- GLTO N/A
- PW 71.26
- 52 Week Low
- GLTO $2.01
- PW $0.63
- 52 Week High
- GLTO $15.13
- PW $2.75
- Technical
- Relative Strength Index (RSI)
- GLTO 38.87
- PW 57.74
- Support Level
- GLTO $3.10
- PW $1.14
- Resistance Level
- GLTO $3.65
- PW $1.21
- Average True Range (ATR)
- GLTO 0.31
- PW 0.05
- MACD
- GLTO -0.06
- PW 0.00
- Stochastic Oscillator
- GLTO 10.61
- PW 40.17
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About PW Power REIT (MD)
Power REIT is an internally managed real estate investment trust (REIT) that owns a portfolio of real estate assets related to transportation, energy infrastructure, and Controlled Environment Agriculture (CEA) in the United States. Its investment portfolio comprises solar farm lands, railroad real estate, and various Controlled Environment Agriculture properties in the form of greenhouses for the cultivation of food and cannabis. In addition, the company is focused on opportunities in the form of investing in distressed situations, including debt and other types of secured interests in real estate, distressed properties, and real estate-related companies.